Literature DB >> 16304193

A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.

S C Barr1, K L Warner, B G Kornreic, J Piscitelli, A Wolfe, L Benet, J H McKerrow.   

Abstract

Cruzain is an essential cysteine protease of Trypanosoma cruzi and a therapeutic target for Chagas' disease. Eight dogs were infected with T. cruzi; three were treated with an inhibitor of cruzain, K777, for 14 days. Treatment with K777 abrogated myocardial damage by T. cruzi, as documented by histopathological lesion scores and serum troponin I levels.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16304193      PMCID： PMC1315979          DOI： 10.1128/AAC.49.12.5160-5161.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Trypanosoma cruzi: role of the immune response in the natural resistance of inbred strains of mice.

Authors:  T Trischmann; H Tanowitz; M Wittner; B Bloom
Journal:  Exp Parasitol       Date:  1978-08       Impact factor: 2.011

Review 2.  Cysteine proteases of parasitic organisms.

Authors:  M Sajid; J H McKerrow
Journal:  Mol Biochem Parasitol       Date:  2002-03       Impact factor: 1.759

3.  Electrocardiographic and echocardiographic features of trypanosomiasis in dogs inoculated with North American Trypanosoma cruzi isolates.

Authors:  S C Barr; R A Holmes; T R Klei
Journal:  Am J Vet Res       Date:  1992-04       Impact factor: 1.156

4.  Schizodeme analysis of Trypanosoma cruzi stocks from South and Central America by analysis of PCR-amplified minicircle variable region sequences.

Authors:  H Avila; A M Goncalves; N S Nehme; C M Morel; L Simpson
Journal:  Mol Biochem Parasitol       Date:  1990 Sep-Oct       Impact factor: 1.759

5.  Chronic Trypanosoma cruzi infection in dogs: 11 cases (1987-1996).

Authors:  K M Meurs; M A Anthony; M Slater; M W Miller
Journal:  J Am Vet Med Assoc       Date:  1998-08-15       Impact factor: 1.936

6.  Pathologic features of dogs inoculated with North American Trypanosoma cruzi isolates.

Authors:  S C Barr; S P Schmidt; C C Brown; T R Klei
Journal:  Am J Vet Res       Date:  1991-12       Impact factor: 1.156

7.  Serologic and blood culture survey of Trypanosoma cruzi infection in four canine populations of southern Louisiana.

Authors:  S C Barr; V A Dennis; T R Klei
Journal:  Am J Vet Res       Date:  1991-04       Impact factor: 1.156

8.  Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.

Authors:  J C Engel; P S Doyle; I Hsieh; J H McKerrow
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307
  8 in total
  47 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Divergent modes of enzyme inhibition in a homologous structure-activity series.

Authors:  Rafaela S Ferreira; Clifford Bryant; Kenny K H Ang; James H McKerrow; Brian K Shoichet; Adam R Renslo
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

3.  Synthesis of macrocyclic trypanosomal cysteine protease inhibitors.

Authors:  Yen Ting Chen; Ricardo Lira; Elizabeth Hansell; James H McKerrow; William R Roush
Journal:  Bioorg Med Chem Lett       Date:  2008-06-10       Impact factor: 2.823

4.  Two approaches to discovering and developing new drugs for Chagas disease.

Authors:  J H McKerrow; P S Doyle; J C Engel; L M Podust; S A Robertson; R Ferreira; T Saxton; M Arkin; I D Kerr; L S Brinen; C S Craik
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

5.  Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.

Authors:  Bryan T Mott; Rafaela S Ferreira; Anton Simeonov; Ajit Jadhav; Kenny Kean-Hooi Ang; William Leister; Min Shen; Julia T Silveira; Patricia S Doyle; Michelle R Arkin; James H McKerrow; James Inglese; Christopher P Austin; Craig J Thomas; Brian K Shoichet; David J Maloney
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

6.  Reversible cysteine protease inhibitors show promise for a Chagas disease cure.

Authors:  Momar Ndao; Christian Beaulieu; W Cameron Black; Elise Isabel; Fabio Vasquez-Camargo; Milli Nath-Chowdhury; Frédéric Massé; Christophe Mellon; Nathalie Methot; Deborah A Nicoll-Griffith
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

7.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.

Authors:  Ajit Jadhav; Rafaela S Ferreira; Carleen Klumpp; Bryan T Mott; Christopher P Austin; James Inglese; Craig J Thomas; David J Maloney; Brian K Shoichet; Anton Simeonov
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

8.  Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.

Authors:  Katrien Brak; Iain D Kerr; Kimberly T Barrett; Nobuhiro Fuchi; Moumita Debnath; Kenny Ang; Juan C Engel; James H McKerrow; Patricia S Doyle; Linda S Brinen; Jonathan A Ellman
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

9.  Computational identification of uncharacterized cruzain binding sites.

Authors:  Jacob D Durrant; Henrik Keränen; Benjamin A Wilson; J Andrew McCammon
Journal:  PLoS Negl Trop Dis       Date:  2010-05-11

10.  In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.

Authors:  Yen Ting Chen; Linda S Brinen; Iain D Kerr; Elizabeth Hansell; Patricia S Doyle; James H McKerrow; William R Roush
Journal:  PLoS Negl Trop Dis       Date:  2010-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.